Table 1.

New product approvals

Victoza (liraglutide [rDNA origin] injection)	Novo Nordisk (Copenhagen)	The US Food and Drug Administration approved the new drug application for Victoza, the first once-daily human glucagon-like peptide-1 (GLP-1) analog for type 2 diabetes. Victoza is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type-2 diabetes mellitus.
Xiaflex (collagenase clostridium histolyticum)	BioSpecifics Technologies (Lynbrook, New York) and Auxilium Pharmaceuticals (Malvern, Pennsylvania)	The US Food and Drug Administration approved Xiaflex for adults with Dupuytren's contracture with a palpable cord. Xiaflex consists of two microbial collagenases in a defined mass ratio, Collagenase AUX-1 and Collagenase AUX-II, which are isolated and purified from the fermentation of Clostridium histolyticum bacteria.